Mylan Inc. obtained a temporary restraining order from the US District Court for the District of New Jersey that prohibits Apotex from "using, offering to sell, selling or shipping or otherwise launching or importing" all three strengths of a generic version of GlaxoSmithKline's Paxil CR, Paroxetine Hydrochloride (HCl) Extended-release (ER) tablets, 12.5 mg, 25 mg and 37.5 mg.

The order also prohibits GlaxoSmithKline from supplying Apotex with a generic version of the product. The order was entered on September 21, and the court has scheduled further hearings on the matter for October 18.

Mylan is currently selling all three strengths of Paroxetine HCl ER.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories.